TTRXTurn Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of Turn Therapeutics Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TTRXEsta | $395M#8 | — | 575.0x#15 | — | — | -80.6%#12 | — | -465.0%#13 | — | — | — | — |
| ARCT | $450M#1 | — | 2.6x#8 | 5.5x#4 | -46.1%#6 | 18.7%#4 | -93.0%#2 | -38.3%#4 | -136.2%#2 | — | -12.7%#7 | — |
| PRTA | $429M#2 | — | 1.5x#5 | 44.3x#8 | -92.8%#7 | -99.6%#13 | -2216.4%#8 | -85.1%#11 | — | — | 2.2%#5 | — |
| SPRY | $421M#3 | — | 33.7x#13 | 5.0x#2 | -5.5%#5 | -2241.8%#16 | -212.9%#4 | -1369.1%#15 | -177.6%#3 | — | — | — |
| AVIR | $419M#4 | — | 2.1x#6 | 1.2x#1 | 622.5%#1 | 6.0%#6 | -51.5%#1 | -77.4%#9 | — | — | 72.3%#2 | — |
| GTBP | $410M#5 | 1.7x#1 | 114.8x#14 | — | — | -115.4%#15 | — | -794.5%#14 | — | — | -54.8%#12 | 0.1%#1 |
| LRMR | $408M#6 | — | 3.2x#10 | — | — | -105.5%#14 | — | -130.1%#12 | -350.3%#4 | — | -1.0%#6 | — |
| RZLT | $402M#7 | — | 3.4x#11 | — | — | -8.7%#8 | — | -63.7%#7 | -72.2%#1 | — | -44.1%#10 | — |
| BBOT | $391M#9 | — | 1.2x#3 | — | — | -80.5%#11 | — | -41.5%#5 | — | — | -50.4%#11 | — |
| BNTC | $389M#10 | — | 2.2x#7 | — | -100.0%#8 | -20.1%#10 | — | -25.7%#3 | — | — | -17.9%#8 | — |
| BIOA | $375M#11 | — | 1.0x#1 | 41.7x#7 | — | -13.4%#9 | -1031.5%#7 | -21.5%#1 | — | — | — | — |
| RCKT | $375M#12 | — | 1.0x#2 | — | — | 13.8%#5 | — | -60.5%#6 | — | — | 6.1%#4 | — |
| GALT | $374M#13 | — | — | — | — | 34.5%#1 | — | — | — | — | -17.9%#9 | — |
| EVMN | $362M#14 | 1.8x#2 | 1.3x#4 | 27.9x#5 | 85.7%#2 | -3.1%#7 | -623.6%#5 | -24.8%#2 | — | — | — | — |
| PRLD | $361M#15 | — | 2.7x#9 | 29.7x#6 | 73.4%#3 | 21.8%#3 | -861.3%#6 | -74.4%#8 | — | — | 303.6%#1 | — |
| ENTA | $358M#16 | — | 3.5x#12 | 5.5x#3 | -3.4%#4 | 29.4%#2 | -130.7%#3 | -81.0%#10 | — | — | 64.0%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-15.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice